BROMOCRIPTINE 5 MG
BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) : 5 MG · DIN 02230454 · AA PHARMA INC
Health Canada status: MARKETED
What is BROMOCRIPTINE?
BROMOCRIPTINE 5 MG contains BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02230454, held by AA PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BROMOCRIPTINE used for?
BROMOCRIPTINE (Bromocriptine Mesylate) is indicated for: Galactorrhea with or without amenorrhea due to hyperprolactinemia. Prolactin-dependent menstrual disorders and infertility: e.g. secondary amenorrhea, ovulatory insufficiency and short luteal phase. Prolactin-secreting adenomas: as a treatment for inoperable macroadenomas or prior to surgery in order to facilitate removal, and as an alternative to surgery in patients with microadenomas. Prolactin-dependent male hypogonadism. Acromegaly: the first-line treatment of this condition is by surgery or radiotherapy. BROMOCRIPTINE (bromocriptine mesylate) may be a useful adjunct to such treatment, and can be used as monotherapy in special cases. Parkinson’s Disease: BROMOCRIPTINE is effective when used as adjunct therapy to levodopa in the symptomatic management of Parkinson’s Disease. Used concomitantly with levodopa, bromocriptine facilitates the use of lower doses of levodopa in early disease and attenuates the rate of increase in the levodopa dosages on long-term usage. In this way the risk of long – term complications such as prominent dyskinesias and/or end-of-dose failure can be reduced.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is BROMOCRIPTINE called?
The same molecule, BROMOCRIPTINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Parlodel | Latin | Australia, Morocco |
| Aspen Bromocriptine | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02230454 |
|---|---|
| Brand name | BROMOCRIPTINE |
| Generic / active ingredient | BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) : 5 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 5 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BC01 BROMOCRIPTINE |
| AHFS class | 28:36.20.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Oct-2012 |
| Original market date | 1997-01-08 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230454 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230454 |
| Brand name | BROMOCRIPTINE |
| Active ingredient / INN | BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) : 5 MG |
| ATC code | N04BC01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N04 |
| AHFS class | 28:36.20.04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | AA PHARMA INC |
How is it stored and handled?
null
How is it supplied?
Available in bottles of 100.
Which pack is which?
| Strength on the label | 5 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Packaging as described in the monograph | Available in bottles of 100. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code N04BC01 BROMOCRIPTINE. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BROMOCRIPTINE | 2.5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02087324 |
Who else supplies BROMOCRIPTINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BROMOCRIPTINE appears in 7 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BROMOCRIPTINE cost around the world?
BROMOCRIPTINE is listed on 5 national price registers Nexara tracks, across 19 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 2 | 9 | 03 Sep 2026 |
| Australia | ex-manufacturer | 1 | 3 | 08 Sep 2026 |
| Saudi Arabia | public | 1 | 3 | 01 Sep 2026 |
| South Africa | single exit price | 3 | 3 | 01 Sep 2026 |
| Morocco | PPV (public price) | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.